The data from many clinical studies confirmed that CD19-CARTs can induce prolonged remissions in patients with B-cell lymphomas, often with minimal long-term toxicities, and are curative for a subset of patients [500]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.